Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | RB1 | P06400 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10447002 | 0.98 | GRIN2B (0.57) | GRIN2BFYNACHEBACE1BCHE | |
| SCHEMBL3834622 | 0.85 | GRIN2B (0.77) | GRIN2BFYNACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL10446804 | 0.83 | GRIN2B (0.74) | GRIN2BFYNACHEBACE1BCHE | |
| SCHEMBL5358070 | 0.82 | GRIN2B (0.58) | GRIN2BFYNACHEBACE1BCHE | |
| SCHEMBL6833760 | 0.82 | GRIN2B (0.58) | GRIN2BFYNACHEBACE1BCHE | |
| SCHEMBL13357772 | 0.82 | GRIN2B (0.58) | GRIN2BFYNACHEBACE1BCHE | |
| SCHEMBL8338757 | 0.81 | GRIN2B (0.54) | GRIN2BFYNSIGMAR1MEN1RAB9A | |
| SCHEMBL5361147 | 0.81 | KMT2A (0.60) | GRIN2BFYNMEN1KMT2ADRD2 | |
| SCHEMBL5373232 | 0.81 | ACHE (0.58) | GRIN2BFYNACHEBACE1BCHE | |
| Hydrochloric Acid SCHEMBL10447191 | 0.81 | POLB (0.62) | GRIN2BFYNACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | claimed |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2006-08-10 | — | — | US | claimed |
| EP-1487796-A4 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | claimed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7148225-B2 | Substituted biaryl amides as C5A receptor modulators | NEUROGEN CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2006-08-10 | — | — | US | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | GRIN2B 1318/4885FYN 1219/4885ACHE 2569/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | GRIN2B 1350/4885FYN 1208/4885ACHE 2431/4885 |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | GRIN2B 1350/4885FYN 1208/4885ACHE 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.